To paraphrase a line poorly credited to Einstein: “Insanity is composed of repeating the same mistakes and expecting other results. “The classes have gone unnoticed. To be precise, why haven’t studies and progression of a real-time diagnostic plan and host defense treatments been funded?
I must begin by acknowledging a basic truth, for over two hundred years, vaccines have saved more lives than any other mixed therapy. However, the progression of many effective vaccines for coverage against trendy infections has been, so far, disappointing. results.
In 1987, studies on the progression of HIV vaccines began. To date, there is no vaccine against HIV. Applicants’ clinical trials remain a challenge. And when you take a look at seasonal flu vaccines, because they rely on identifying the “best guess” strain, they demonstrate no more than 60% efficacy; In some years, the power drops by up to 10%. The need for a universal influenza vaccine has long been recognized, dozens of approaches have been announced over a 40-year period, only a handful of applicants have reached the complex level of clinical trials. And none have succeeded yet.
From February to April 11, 120,820 new weekly Covid-19 infections, 1,773 new weekly deaths and 1,807 new daily hospitalizations were reported. (Remember that there is no national strategy for reporting on Covid-19, so the actual numbers are higher. )Nor is it explained why the new vaccines will be more efficient.
Given those grim realities, where would the $5 billion studies and progression fund be most effective?As I’ll do below, resources will need to be faithful to crafting a comprehensive real-time diagnostic plan and, just as importantly, host advocacy therapies.
Covid-19 vaccines evolved into works preventing the virus from becoming infected, thus keeping it under control. The problem is that while the vaccine is expressed in its mode of action by binding to an expressed viral structure, the virus mutates and modifies. This vulnerable point to evade vaccine binding. When it can’t attach to the virus, the vaccine becomes less effective at preventing infection and will instead have to rely on other, as-yet-undefined immunity to protect against death.
Despite this fact, there will be supporters of the vaccine and booster strategy. However, the public has become less self-confident when it comes to vaccination recommendations. Given that just over 50% of Americans get a flu shot each year, that number is unlikely to be higher for a new Covid-19 vaccine or booster shot. The only exception to this prediction would be the progression of a pan-coronavirus vaccine administered as an unmarried treatment. And as discussed above, although theoretically possible, generations of studies have not yielded the desired result.
These remedies are especially important for others with weakened immune systems, but they cannot offer comprehensive coverage against Covid-19 for the network in general. The reason for this is that they are too fast and are meant to attack an Express viral variant. Viruses mutate to evade host defenses and therapy. An undeniable mutation can render antibody remedies ineffective.
Why not continue to expand antibody remedies against each new variant as they emerge?Unfortunately, the expansion, manufacture, distribution and administration of a new antibody remedy takes too long. Existing dominant strain, the virus has had time to mutate by creating a new dominant strain that renders the remedy opposite the previous strain ineffective. Because of this reduced efficacy cycle, the FDA withdrew its initial EUA authorization for several monoclonal therapies. For polyclonal antibody remedies, however, they are most effective when administered before the patient becomes clinically ill.
Another challenge that results from the use of antibody remedies is the progression of antibody-dependent enhancement (ADE). ADE occurs when antibodies generate an immune reaction (or are injected through antibody therapy) recognize and bind to a pathogen but cannot save it from infection. Instead, those antibodies serve as “Trojan horses” that allow the pathogen to enter cells and produce a poor immune reaction leading to endemic inflammation.
A rarely discussed challenge resulting from antibody treatment is the imprinting progression of the immune formula. Immune fingerprinting is a phenomenon in which initial exposure to a virus strain initiates well the reminiscence of B cells and limits the progression of reminiscence B cells and neutralizing antibodies opposed to new ones. variant strains of the virus. If a patient’s immune formula has been tagged through a previous Covid-19 infection, an upcoming Covid-19 infection with a new variant will stimulate the immune formula to produce antibodies opposite to the older variant than the new one resulting in an out-of-control infection.
What’s the $5 billion in COVID funding?
Understanding the need to harbor defense treatments requires a fundamental wisdom of the body’s supplemental immune formula whose disruptive effects on serious illness.
The complementary formula has 3 main components, with an express mode of action. The 3 branches or pathways of the supplement formula are the classical, lectin and choice pathways.
The classical supplement pathway is a key component of the adaptive or learned immune reaction and is activated through antibodies bound to foreign substances. It depends on the body’s ability to fight infection.
The supplement’s lectin pathway plays a central role in the body’s innate immune response. The lectin pathway is activated through patterns of molecules in pathogens and in the cells of the body.
The channel of choice is an amplification loop that operates in the background of the supplementation system, and its activity is greater with the activation of the classical and/or lectin channels, reinforcing the movements of these two pathways.
The formula of the supplement is extremely complex and there is still much to learn. Generally speaking, the formula reacts to triggers that activate it once it was risked through a pathogen or toxin. When the risk has passed, regulatory triggers remove or close the formula, returning it to its follow-up state.
In severe Covid-19 infections, the formula is “hijacked” and dragged into overdrive which, in effect, turns the body’s defense formula into the opposite of itself. Within the supplement formula, the driving force of dysregulation in Covid-19 has been shown to be the lectin pathway. According to one study, “early and persistent activation of supplements is thought to play a key role in the pathogenesis of COVID-19. Complement activation products organize a pro-inflammatory environment that may be critical for the induction and maintenance of a severe inflammatory reaction to SARS-CoV-2 by recruiting cells from the cellular immune formula to sites of infection and changing their activation state to an inflammatory phenotype. “
When the lectin pathway is accelerated, it produces bad and destructive inflammation. In severe Covid-19 infections, the resulting uncontrolled inflammation damages all organ systems. It is also important, in cases of moderate or severe Covid-19, the hyperactivation of the lectin pathway. It impairs or suppresses the ability of the classical pathway to fight infection.
On April 4, 2023, a company funded through German government grants, InflaRx N. V. (Nasdaq: IFRX) obtained Emergency Use Authorization (EUA) from the U. S. FDA. The U. S. Department of Health and Drug Administration has been used for vilobelimab for the treatment of severe COVID-19 in critically ill patients. Vilobelimab is a first-in-class human supplement C5a monoclonal antibody. Part of the supplement’s formula, C5a, along with C3a, are anaphylatoxins. Anaphylatoxins are potent chemoattractants that recruit and activate various inflammatory cells, adding macrophages, eosinophils, and neutrophils. The key takeaway here can be summed up through InflaRx’s chief executive, Professor Niels Riedeman, when he told me that the supplement formula “is implicated in many diseases and the FDA has identified the wonderful need for a new way to treat critically ill Covid-19 patients. “
Professor Riedeman believes that the InflaRx technique can be potentially effective in a wide diversity of complement-related diseases, adding chronic inflammatory diseases hidradenitis suppurativa (HS), ANCA (cytoplasmic neutrophil antibodies) – related vasculitis (AAV), pyoderma gangrenosum (PG) and mobile cutaneous squamous cell carcinoma (cSCC).
Taking a unique technique for the treatment of complement-related diseases and disorders, a Seattle-based biotechnology company, Omeros Corp. , (Nasdaq: OMER) aims at pre-inhibition of choice and lectin pathways. Omeros is seeking FDA approval for its primary lectin inhibitor pathway, narsoplimab, for the treatment of thrombotic microangiopathy related to mobile hematopoietic stem transplantation (TA-TMA). TA-TMA has been shown to have a mechanism similar to that of Covid-19, that is, it damages the mobiles that line the blood vessels in the frame. As stated above, this mobile damage directly ignites the lectin pathway. Publications demonstrate the favorable role of narsoplimab and the activation of the lectin pathway in Covid-19. other inflammatory mediators that wreak havoc in the Covid-19 picture, leaving intact the anti-infective capacity of the classical pathway.
Rapid diagnostics are for the timely identification of pathogens. Once a pathogen is identified, targeted therapy begins, which includes a well-functioning host defense system.
Severe Covid-19 infection makes patients vulnerable to life-threatening sepsis. Many other pathogens and diseases also disrupt the body’s immune system and cause uncontrolled inflammation. It is vital to have access to immediate diagnostics to identify not only the Covid-19 virus, but all pathogens, whether viral, bacterial or fungal.
Instead of repeating the mistakes of the afterlife and making an investment in modalities that have not lived up to expectations, it would be wise to adopt a mindset shift and expand immediate diagnostics to identify early fitness threats and repair and harbor defenses to save you and your family members. repair the damage caused by these threats.
Five billion dollars well placed would go a long way toward securing a healthier future. We will have to be informed of our mistakes, not repeat them.